Suppression of human papillomavirus gene expression in vitro and in vivo by herpes simplex virus type 2 infection

Virology

Volumn 314, Issue 1, 2003, Pages 147-160

  Fang, L ^a   Ward, M G ^a   Welsh, P A ^a   Budgeon, L R ^b   Neely, E B ^a   Howett, M K ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; Cervical neoplasias; Herpes simplex virus type 2; Human papillomavirus; Human xenografts; Sexually transmitted diseases; Virus host shutoff

Indexed keywords

ARTICLE; BIOASSAY; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DISEASE COURSE; DOWN REGULATION; GENE EXPRESSION; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 2; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; REDUCTION; RISK FACTOR; UTERINE CERVIX CARCINOMA; VAGINA EPITHELIUM; VIRUS TRANSCRIPTION; VIRUS TRANSFORMATION; WART VIRUS; XENOGRAFT;

HUMAN HERPESVIRUS 2; HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPES; PAPILLOMAVIRUS; SIMPLEXVIRUS;

EID: 0141792172     PISSN: 00426822     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0042-6822(03)00440-9     Document Type: Article

References (53)

1. Adelman S.F., Howett M.K., Rapp F. Quantification of plasminogen activator activity associated with herpesvirus-transformed cells. J. Gen. Virol. 50:(1):1980;101-110.
2. Andreansky S., Soroceanu L., Flotte E.R., Chou J., Markert J.M., Gillespie G.Y., Roizman B., Whitley R.J. Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 57:(8):1997;1502-1509.
3. Arbuzov V.A. Stabilization of polyribosomal mRNA in rat liver cells under protein synthesis inhibition by cycloheximide. Biokhimiia. 43:(5):1978;838-850.
4. Berezutskaya E., Bagchi S. The human papillomavirus E7 oncoprotein functionally interacts with the S4 subunit of the 26 S proteasome. J. Biol. Chem. 272:(48):1997;30135-30140.
5. Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V. Prevalence of human papillomavirus in cervical cancer a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group . J. Natl. Cancer Inst. 87:(11):1995;796-802.
6. Carew J.F., Kooby D.A., Halterman M.W., Federoff H.J., Fong Y. Selective infection and cytolysis of human head and neck squamous cell carcinoma with sparing of normal mucosa by a cytotoxic herpes simplex virus type 1 (G207). Hum. Gene Ther. 10:(10):1999;1599-1606.
7. Dhanwada K.R., Garrett L., Smith P., Thompson K.D., Doster A., Jones C. Characterization of human keratinocytes transformed by high risk human papillomavirus types 16 or 18 and herpes simplex virus type 2. J. Gen. Virol. 74:(Pt. 6):1993;955-963.
8. Dhanwada K.R., Veerisetty V., Zhu F., Razzaque A., Thompson K.D., Jones C. Characterization of primary human fibroblasts transformed by human papilloma virus type 16 and herpes simplex virus type 2 DNA sequences. J. Gen. Virol. 73:(Pt. 4):1992;791-799.
9. Di Luca D., Rotola A., Pilotti S., Monini P., Caselli E., Rilke F., Cassai E. Simultaneous presence of herpes simplex and human papilloma virus sequences in human genital tumors. Int. J. Cancer. 40:(6):1987;763-768.
10. Dickson M.A., Hahn W.C., Ino Y., Ronfard V., Wu J.Y., Weinberg R.A., Louis D.N., Li F.P., Rheinwald J.G. Human keratinocytes that express hTERT and also bypass a p16(INK4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol. Cell. Biol. 20:(4):2000;1436-1447.
11. DiPaolo J.A., Popescu N.C., Alvarez L., Woodworth C.D. Cellular and molecular alterations in human epithelial cells transformed by recombinant human papillomavirus DNA. Crit. Rev. Oncog. 4:(4):1993;337-360.
12. DiPaolo J.A., Woodworth C.D., Coutlee F., Zimonic D.B., Bryant J., Kessous A. Relationship of stable integration of herpes simplex virus-2 Bg/II N subfragment Xho2 to malignant transformation of human papillomavirus-immortalized cervical keratinocytes. Int. J. Cancer. 76:(6):1998;865-871.
13. DiPaolo J.A., Woodworth C.D., Popescu N.C., Koval D.L., Lopez J.V., Doniger J. HSV-2-induced tumorigenicity in HPV16-immortalized human genital keratinocytes. Virology. 177:(2):1990;777-779.
14. Galloway D.A., McDougall J.K. Transformation of rodent cells by a cloned DNA fragment of herpes simplex virus type 2. J. Virol. 38:(2):1981;749-760.
15. Galloway D.A., McDougall J.K. The oncogenic potential of herpes simplex viruses evidence for a "hit- and-run" mechanism . Nature. 302:(5903):1983;21-24.
16. Galloway D.A., Nelson J.A., McDougall J.K. Small fragments of herpesvirus DNA with transforming activity contain insertion sequence-like structures. Proc. Natl. Acad. Sci. USA. 81:(15):1984;4736-4740.
17. Giard D.J., Aaronson S.A., Todaro G.J., Amstein P., Kersey J.H., Dosik H., Parks W.P. In vitro cultivation of human tumors establishment of cell lines derived from a series of solid tumors . J. Natl. Cancer Inst. 51:(5):1973;1417-1423.
18. Gius D., Laimins L.A. Activation of human papillomavirus type 18 gene expression by herpes simplex virus type 1 viral transactivators and a phorbol ester. J. Virol. 63:(2):1989;555-563.
19. Hamouda T., McPhee R., Hsia S.C., Read G.S., Holland T.C., King S.R. Inhibition of human immunodeficiency virus replication by the herpes simplex virus virion host shutoff protein. J. Virol. 71:(7):1997;5521-5527.
20. Hara Y., Kimoto T., Okuno Y., Minekawa Y. Effect of herpes simplex virus on the DNA of human papillomavirus 18. J. Med. Virol. 53:(1):1997;4-12.
21. Hildesheim A., Mann V., Brinton L.A., Szklo M., Reeves W.C., Rawls W.E. Herpes simplex virus type 2 a possible interaction with human papillomavirus types 16/18 in the development of invasive cervical cancer . Int. J. Cancer. 49:(3):1991;335-340.
22. Howett M.K., Welsh P.A., Budgeon L.R., Ward M.G., Neely E.B., Patrick S.D., Weisz J., Kreider J.W. Transformation of human vaginal xenografts by human papillomavirus type 11 prevention of infection with a microbicide from the alkyl sulfate chemical family . Pathogenesis. 1:(4):2000;265-276.
23. Jariwalla R.J., Aurelian L., Ts'o P.O. Tumorigenic transformation induced by a specific fragment of DNA from herpes simplex virus type 2. Proc. Natl. Acad. Sci. USA. 77:(4):1980;2279-2283.
24. Jones C. Cervical cancer is herpes simplex virus type II a cofactor? Clin. Microbiol. Rev. 8:(4):1995;549-556.
25. Karlen S., Offord E.A., Beard P. Herpes simplex virions interfere with the expression of human papillomavirus type 18 genes. J. Gen. Virol. 74:(Pt. 6):1993;965-973.
26. Kenney S., Pagano J.S. Viruses as oncolytic agents a new age for "therapeutic" viruses? J. Natl. Cancer Inst. 86:(16):1994;1185-1186.
27. Kramm C.M., Chase M., Herrlinger U., Jacobs A., Pechan P.A., Rainov N.G., Sena-Esteves M., Aghi M., Barnett F.H., Chiocca E.A., Breakefield X.O. Therapeutic efficiency and safety of a second-generation replication-conditional HSV1 vector for brain tumor gene therapy. Hum. Gene Ther. 8:(17):1997;2057-2068.
28. Kreider J.W., Howett M.K., Leure-Dupree A.E., Zaino R.J., Weber J.A. Laboratory production in vivo of infectious human papillomavirus type 11. J. Virol. 61:(2):1987;590-593.
29. Kreider J.W., Howett M.K., Wolfe S.A., Bartlett G.L., Zaino R.J., Sedlacek T., Mortel R. Morphological transformation in vivo of human uterine cervix with papillomavirus from condylomata acuminata. Nature. 317:(6038):1985;639-641.
30. Lehtinen M., Koskela P., Jellum E., Bloigu A., Anttila T., Hallmans G., Luukkaala T., Thoresen S., Youngman L., Dillner J., Hakama M. Herpes simplex virus and risk of cervical cancer a longitudinal, nested case-control study in the nordic countries . Am. J. Epidemiol. 156:(8):2002;687-692.
31. Lou E., Kellman R.M., Shillitoe E.J. Effect of herpes simplex virus type-1 on growth of oral cancer in an immunocompetent, orthotopic mouse model. Oral Oncol. 38:(4):2002;349-356.
32. Ludmerer S.W., McClements W.L., Wang X.M., Ling J.C., Jansen K.U., Christensen N.D. HPV11 mutant virus-like particles elicit immune responses that neutralize virus and delineate a novel neutralizing domain. Virology. 266:(2):2000;237-245.
33. McCusker C.T., Bacchetti S. The responsiveness of human papillomavirus upstream regulatory regions to herpes simplex virus immediate early proteins. Virus Res. 11:(3):1988;199-207.
34. McDougall J.K. Immortalization and transformation of human cells by human papillomavirus. Curr. Top. Microbiol. Immunol. 186:1994;101-119.
35. Pak A.S., Everly D.N., Knight K., Read G.S. The virion host shutoff protein of herpes simplex virus inhibits reporter gene expression in the absence of other viral gene products. Virology. 211:(2):1995;491-506.
36. Phelan A., Clements J.B. Posttranscriptional regulation in herpes simplex virus. Semin. Virol. 8:1998;309-318.
37. Pisani S., Fioriti D., Conte M.P., Chiarini F., Seganti L., Degener A.M. Involvement of herpes simplex type 2 in modulation of gene expression of human papillomavirus type 18. Int. J. Immunopathol. Pharmacol. 15:(1):2002;59-63.
38. Randazzo B.P., Bhat M.G., Kesari S., Fraser N.W., Brown S.M. Treatment of experimental subcutaneous human melanoma with a replication-restricted herpes simplex virus mutant. J. Invest. Dermatol. 108:(6):1997;933-937.
39. Robinson S.P., Langan-Fahey S.M., Jordan V.C. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts. Eur. J. Cancer Clin. Oncol. 25:(12):1989;1769-1776.
40. Scheffner M. Ubiquitin, E6-AP, and their role in p53 inactivation. Pharmacol. Ther. 78:(3):1998;129-139.
41. Schwarz E., Freese U.K., Gissmann L., Mayer W., Roggenbuck B., Stremlau A., zur Hausen H. Structure and transcription of human papillomavirus sequences in cervical carcinoma cells. Nature. 314:(6006):1985;111-114.
42. Smiley J.R., Elgadi M.M., Saffran H.A. Herpes simplex virus vhs protein. Methods Enzymol. 342:2001;440-451.
43. Smith J.S., Herrero R., Bosetti C., Munoz N., Bosch F.X., Eluf-Neto J., Castellsague X., Meijer C.J., Van Den Brule A.J., Franceschi S., Ashley R. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. J. Natl. Cancer Inst. 94:(21):2002;1604-1613.
44. Smith L.H., Foster C., Hitchcock M.E., Leiserowitz G.S., Hall K., Isseroff R., Christensen N.D., Kreider J.W. Titration of HPV-11 infectivity and antibody neutralization can be measured in vitro. J. Invest. Dermatol. 105:(3):1995;438-444.
45. Sotlar K., Selinka H.C., Menton M., Kandolf R., Bultmann B. Detection of human papillomavirus type 16 E6/E7 oncogene transcripts in dysplastic and nondysplastic cervical scrapes by nested RT-PCR. Gynecol. Oncol. 69:(2):1998;114-121.
46. Stoler M.H. Human papillomaviruses and cervical neoplasia a model for carcinogenesis . Int. J. Gynecol. Pathol. 19:(1):2000;16-28.
47. Storey A., Massimi P., Dawson K., Banks L. Conditional immortalization of primary cells by human papillomavirus type 18 E6 and EJ-ras defines an E6 activity in G0/G1 phase which can be substituted for mutations in p53. Oncogene. 11:(4):1995;653-661.
48. Vonka V., Kanka J., Hirsch I., Zavadova H., Krcmar M., Suchankova A., Rezacova D., Broucek J., Press M., Domorazkova E., et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. II. Herpes simplex type-2 antibody presence in sera taken at enrollment. Int. J. Cancer. 33:(1):1984;61-66.
49. Vonka V., Kanka J., Jelinek J., Subrt I., Suchanek A., Havrankova A., Vachal M., Hirsch I., Domorazkova E., Zavadova H., et al. Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int. J. Cancer. 33:(1):1984;49-60.
50. Wymer J.P., Aurelian L. Papillomavirus trans-activator protein E2 activates expression from the promoter for the ribonucleotide reductase large subunit from herpes simplex virus type 2. J. Gen. Virol. 71:(Pt 8):1990;1817-1821.
51. zur Hausen H. Molecular pathogenesis of cancer of the cervix and its causation by specific human papillomavirus types. Curr. Top. Microbiol. Immunol. 186:1994;131-156.
52. zur Hausen H. Papillomaviruses causing cancer evasion from host-cell control in early events in carcinogenesis . J. Natl. Cancer Inst. 92:(9):2000;690-698.
53. zur Hausen H., Gissmann L., Schlehofer J.R. Viruses in the etiology of human genital cancer. Prog. Med. Virol. 30:1984;170-186.